CVS Health Sees Unusually High Options Volume (NYSE:CVS)

CVS Health Corporation (NYSE:CVS) saw unusually large options trading activity on Tuesday. Traders purchased 30,223 call options on the company. This is an increase of 52% compared to the average daily volume of 19,874 call options.

Analysts Set New Price Targets

A number of research firms recently commented on CVS. Sanford C. Bernstein raised CVS Health from a “market perform” rating to an “outperform” rating and increased their target price for the company from $91.00 to $94.00 in a research note on Thursday, March 12th. Argus dropped their price target on CVS Health from $91.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, January 28th. Mizuho increased their price objective on CVS Health from $88.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Leerink Partners reissued an “outperform” rating and set a $98.00 price objective on shares of CVS Health in a report on Thursday, March 5th. Finally, Bank of America cut their target price on CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research note on Tuesday, January 27th. Twenty research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $94.95.

CVS Health Stock Performance

NYSE CVS opened at $72.49 on Thursday. The company has a 50-day simple moving average of $76.11 and a two-hundred day simple moving average of $77.70. CVS Health has a 12-month low of $58.35 and a 12-month high of $85.15. The firm has a market cap of $92.22 billion, a price-to-earnings ratio of 52.53, a PEG ratio of 0.75 and a beta of 0.51. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, topping the consensus estimate of $1.00 by $0.09. The firm had revenue of $105.69 billion for the quarter, compared to the consensus estimate of $103.67 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The company’s quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, equities analysts forecast that CVS Health will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd will be given a $0.665 dividend. The ex-dividend date is Thursday, April 23rd. This represents a $2.66 annualized dividend and a yield of 3.7%. CVS Health’s payout ratio is presently 192.75%.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is accelerating a roll‑out of small, pharmacy‑only stores (about 20 planned this year) designed to focus on prescriptions and pharmacist services — a move that could improve margins and serve underserved neighborhoods. CVS Accelerates Rollout of New Pharmacy-Only Store Format
• Positive Sentiment: Company plans to open substantially more locations in 2026 (reports cite roughly 60 new openings after years of net closures), signaling a strategic pivot to grow retail pharmacy revenues and refill volumes. CVS plans to open 60 new stores in 2026 after years of closures
• Positive Sentiment: Unusually large call‑option buying was noted recently (over 30k calls traded), a short‑term bullish signal that can lift near‑term share demand. CVS Health (CVS) Increases Yet Falls Behind Market: What Investors Need to Know
• Positive Sentiment: Analyst coverage remains largely bullish — consensus implies meaningful upside and the majority of sell‑side ratings are positive, supporting investor confidence despite some near‑term headwinds. CVS Health (CVS) Under Analyst Spotlight Following Proposed FTC Settlement Related to Insuling Pricing
• Neutral Sentiment: Omnicare (CVS subsidiary) advanced a court‑supervised sale process and entered an asset purchase agreement with GenieRx, which could simplify the portfolio and free cash but may take time to realize value. Omnicare Advances Court-Supervised Process While Continuing to Deliver Enhanced Value to Customers
• Neutral Sentiment: Piper Sandler trimmed its price target slightly (from $101 to $99) but maintained an overweight rating — a modest tweak that leaves substantial upside in many analysts’ models. Benzinga piece on Piper Sandler price target change
• Negative Sentiment: Regulatory/legal risk remains in focus — coverage has flagged a proposed FTC settlement related to insulin pricing that could create uncertainty or financial exposure depending on final terms. CVS Health (CVS) Under Analyst Spotlight Following Proposed FTC Settlement Related to Insuling Pricing

Institutional Investors Weigh In On CVS Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SOA Wealth Advisors LLC. increased its position in shares of CVS Health by 36.9% in the third quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock valued at $37,000 after acquiring an additional 131 shares during the period. Alteri Wealth LLC boosted its holdings in shares of CVS Health by 3.2% during the third quarter. Alteri Wealth LLC now owns 4,195 shares of the pharmacy operator’s stock worth $316,000 after purchasing an additional 131 shares during the period. TOWER TRUST & INVESTMENT Co grew its stake in shares of CVS Health by 0.8% in the fourth quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock worth $1,247,000 after purchasing an additional 132 shares during the last quarter. Holistic Financial Partners increased its holdings in CVS Health by 4.1% during the 3rd quarter. Holistic Financial Partners now owns 3,397 shares of the pharmacy operator’s stock valued at $256,000 after purchasing an additional 133 shares during the period. Finally, CYBER HORNET ETFs LLC raised its position in CVS Health by 4.1% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock valued at $259,000 after purchasing an additional 134 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.